These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21723790)

  • 1. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Roth JA; Carlson JJ
    Clin Lung Cancer; 2011 Nov; 12(6):393-401. PubMed ID: 21723790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
    Sad LM; Younis SG; Elity MM
    Med Oncol; 2014 Jul; 31(7):58. PubMed ID: 24935625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy.
    Lee HY; Shin JH; Lee KY; Park JK; Sung SW; Kim YS; Kang JH; Kim JO
    Korean J Intern Med; 2019 Mar; 34(2):401-408. PubMed ID: 30184615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
    Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
    J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
    Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
    Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
    Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.